If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 101 - 110 of 281
A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA Versus Bortezomib, Lenalidomide, and Dexamethasone (
CAR-T Clinical trial in Subjects with Newly Diagnosed MM and for Whom HSCT is not planned
Protocol No
JNJ-68284528MMY3004CARTITUDE-5
Renal Metabolism in Salt-Sensitive Human Blood Pressure
Renal Metabolism Study
Protocol No
ENDO-IIT-KIDAMBI-RENAL-METABOL
Categories
A Multicenter, Single-Arm Prospective Study to Evaluate Safety and Efficacy of GLE/PIB 8-Week Treatment in Adults and Adolescents with Acute Hepatitis C Virus (HCV) Infection
Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)
Protocol No
GI-ABBVIE-M20-350
Categories
A Multicenter, Randomized, Double-Blind, Parallel-Group Study To Assess The Efficacy And Safety Of Oral Etrasimod as Induction And Maintenance Therapy For Moderately To Severely Active Crohns Disease
A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease (CULTIVATE)
Protocol No
GI-ARENA-CULTIVATE-CD
Categories
An Open-Label Extension Study of Etrasimod in Subjects with Moderately to Severely Active Ulcerative Colitis
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis (ELEVATE UC OLE)
Protocol No
GI-ARENA-ELEVATE-UC-OLE
Categories
A Two Part Phase IIa/b Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose-ranging Study to Assess Efficacy, Safety, and Tolerability of the Combination of Zibotentan and Dapagliflozin, and Dapagliflozin Monotherapy Versus
Zibotentan and Dapagliflozin Combo, EvAluated in Liver Cirrhosis
Protocol No
GI-AZ-ZEAL
Categories
Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Crohn's Disease: The OPTIMIZE Trial
Proactive Infliximab Optimization Using a PK Dashboard Versus SOC in Patients With Crohn's Disease: The OPTIMIZE Trial
Protocol No
GI-BIDMC-OPTIMIZE
Categories
Assessment of Cardiovascular Risk in Inflammatory Bowel Disease Patients
Cardiovascular Risk in IBD
Protocol No
GI-IIT-SINH-CV-IN-IBD
Categories
A Randomised, Double-blind, Placebo-controlled, Multicentre, Phase 3 Study Evaluating Long-term Efficacy and Safety of Lanifibranor in Adult Patients With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) and Fibrosis 2 (F2)/Fibrosis 3 (F3) Stage of
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) (NATiV3)
Protocol No
GI-INVENTIVA-NATIV3
Categories
A Phase 2b Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely A
Guselkumab and Golimumab in Moderately to Severely Active Ulcerative Colitis
Protocol No
GI-JANSSEN-DUET-UC
Categories